Menu
Network  Clinical Research Site Title Principal Investigator(s)
ONGOING
MTN eThekwini MTN 015: An Observational Cohort Study of Women following HIV-1 seroconversion in Microbicide Trials. Dr Leila Mansoor 
MTN eThekwini MTN 016: HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE Study. Dr Leila Mansoor 
MTN eThekwini MTN 025: A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women. Dr Leila Mansoor 
MTN eThekwini MTN 032: Assessment of ASPIRE and HOPE Adherence: An exploratory sub-study of the ASPIRE and HOPE trials that will utilize qualitative In-Depth Interviews (IDIs) and Focus-Group Discussions (FGDs) Dr Leila Mansoor 
HVTN eThekwini HVTN100: A phase 1/2 randomized, double-blind, placebo- controlled clinical trial of clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C p120/MF59® in HIV Dr Kathryn Mngadi/ Prof Quarraisha Abdool Karim
HVTN eThekwini HVTN 108: A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, NYVAC-HIV, and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants. Dr Kathryn Mngadi
HVTN eThekwini HVTN 703: A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection. Dr Kathryn Mngadi/ Prof Quarraisha Abdool Karim
HVTN eThekwini HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa Dr Kathryn Mngadi/ Prof Quarraisha Abdool Karim
HPTN Vulindlela HPTN 077: A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women Prof Quarraisha Abdool Karim/ Site PI: Dr Halima Dawood
IMPAACT  Umlazi IMPAACT 1077BF Sub-study: ARV Adherence and Exposure – Hair sub-study Dr Daya Moodley/ Prof Quarraisha Abdool Karim
IMPAACT Umlazi IMPAACT P1090: A Phase I/II, open-label trial to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of Etravirine (ETR) in Antiretroviral treatment-experienced HIV-1 infected infants and children, aged >2months to <6years. Dr Kimesh Naidoo/ Prof Daya Moodley/Prof Quarraisha Abdool Karim
IMPAACT Umlazi IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study.   Dr Kimesh Naidoo/ Prof Daya Moodley/Prof Quarraisha Abdool Karim
IMPAACT Umlazi IMPAACT P1093: A Phase I/II, Multi Centre, Open-Label Pharmacokinetic, Safety, Tolerability, and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents Dr Moherndran Archary/ Prof Daya Moodley/ Prof Quarraisha Abdool Karim
COMPLETED
MTN eThekwini MTN 020: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 infection in Women. Dr Gonasagrie Nair
IMPAACT Umlazi IMPAACT 1077BF: Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)  Dr Daya Moodley
IMPAACT Umlazi IMPAACT P1084s: Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health. Dr Daya Moodley
IMPAACT Umlazi IMPAACT P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-exposed neonates at high risk of acquiring HIV-1 infection.   Dr Megeshinee Naidoo/ Dr Daya Moodley/ Prof Quarraisha Abdool Karim
AACTG eThekwini A5221 : STRIDE: A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 < 250 Cells/mm3 Dr Nesri Padayatchi
AACTG eThekwini AACTG A5253: Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals Dr Nesri Padayatchi
AACTG eThekwini AACTG A5255: Faster AFB Identification, Speciation of TB, and Evaluation of Drug Resistance in HIV-Infected Persons Initiating TB Treatment Dr Nesri Padayatchi
AACTG eThekwini AACTG A5274: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens  Dr Nesri Padayatchi
AACTG eThekwini AACTG A5304: Controlled comparison of two moxifloxacin containing treatment shortening regimens with the standard regimen in pulmonary tuberculosis Dr Nesri Padayatchi
HVTN eThekwini / Aurum HVTN 503: A multicenter double-blind randomized placebo-controlled Phase IIB test-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Clade B-based Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1-uninfected adults in South Africa  Prof Koleka Mlisana/ Prof Gavin Churchyard
HVTN eThekwini / Aurum HVTN 082: A descriptive and observational study of long-term outcomes of HIV-1 infection in persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials Dr Craig Innes
MTN eThekwini / Aurum MTN 003: Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women Dr Gonasagrie Nair/ Prof Gavin Churchyard
HPTN Umlazi HPTN 046: Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV Infected Women to Prevent Vertical HIV Transmission During Breastfeeding Dr Daya Moodley
HVTN Aurum HVTN 204:  A placebo-controlled phase II clinical trial to evaluate the safety and Immunogenicity of a multiclade HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, followed by a multiclade recombinant adenoviral vector vaccine boost, VRC-HIVADV014-00-VP, in HIV uninfected adult participants Prof Gavin Churchyard
HVTN Aurum HVTN 404:   Long-term follow-up of HIV-1 Infection in participants who become infected after enrolment in early-phase (Phase 1 and 2a) HIV vaccine protocols or HIV  Dr Craig Innes
HVTN Aurum HVTN 086:  A phase 1 placebo-controlled clinical trial to evaluate the safety and immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis subtype C gp140 with MF59 adjuvant in various vaccination schedules in HIV-uninfected healthy vaccinia-naïve adult participants in South Africa Prof Gavin J Churchyard/ Dr Craig Innes
HVTN Aurum IAVI / B003:   A Phase 1 Placebo-controlled, double-blind, randomized trial to evaluate the safety and immunogenicity of Ad26-ENVA and AD35-ENVA HIV vaccines in healthy HIV-uninfected adult volunteers Dr Liesl Page-Shipp
HVTN Aurum AERAS-402:   A Phase II double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of Aeras-402 in HIV-infected, BCG-vaccinated adults with CD4+ lymphocyte counts greater than 350 cells/mm³ Prof Gavin Churchyard

Centre for the AIDS Programme of Research in South Africa

CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.